Stellate ganglion block for the treatment of breast cancer-related lymphedema in breast cancer survivors

2014 ◽  
Author(s):  
Haifeng Cai ◽  
Jinyin Yan ◽  
Ning Li ◽  
Zhiguo Sun ◽  
Hao Dai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Stellate Ganglion ◽  
Stellate Ganglion Block ◽  
Ganglion Block ◽  
Breast Cancer Related Lymphedema

scholarly journals Comparison of the effects of stellate ganglion block and paroxetine on hot flashes and sleep disturbance in breast cancer survivors

2018 ◽  
Vol Volume 10 ◽  
pp. 4831-4837 ◽  
Author(s):  
Poupak Rahimzadeh ◽  
Farnad Imani ◽  
Nahid Nafissi ◽  
Behzad Ebrahimi ◽  
Seyed Hamid Reza Faiz
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Sleep Disturbance ◽  
Breast Cancer Survivors ◽  
Stellate Ganglion ◽  
Hot Flashes ◽  
Stellate Ganglion Block ◽  
Ganglion Block

scholarly journals Comparison Between the Effectiveness of Complex Decongestive Therapy and Stellate Ganglion Block in Patients with Breast Cancer-Related Lymphedema: A Randomized Controlled Study

2018 ◽  
Vol 3 (22;3) ◽  
pp. 255-263
Author(s):  
Kwan Sik Seo
Keyword(s):  
Breast Cancer ◽  
Stellate Ganglion ◽  
Stellate Ganglion Block ◽  
Ganglion Block ◽  
Complex Decongestive Therapy ◽  
Significant Difference ◽  
Breast Cancer Related Lymphedema ◽  
Eq Vas ◽  
Decongestive Therapy

Background: Breast cancer-related lymphedema (BCRL) of the upper extremities often follows breast cancer treatment. Although complex decongestive therapy (CDT) is currently the standard treatment for BCRL, stellate ganglion block (SGB) has also been reported to be effective. Objectives: This study aimed to determine the effectiveness of SGB in the treatment of BCRL, and to assess the impact of the treatment on the quality of life (QoL) compared to CDT. Study Design: A randomized controlled trial. Setting: A single academic hospital, outpatient setting. Methods: A total of 38 patients with BCRL were recruited. Patients were randomly divided into 2 groups. Patients enrolled in the CDT group underwent 10 sessions of CDT for 2 weeks, whereas patients in the SGB group received 3 consecutive SGBs every 2 weeks. Changes in circumference, volume, and bioimpedance in the upper extremity were measured at baseline and 2 weeks after treatment and compared between the 2 groups. EuroQol-5 dimensions (EQ-5D) and EuroQol visual analog scale (EQ VAS) for QoL and subjective improvement were monitored. Results: In both groups, side-to-side difference of circumference after the treatment was decreased significantly from baseline (P < 0.05), and side-to-side difference of volume was reduced significantly in the SGB group (P < 0.05). No statistically significant difference was noted in the treatment effect between the 2 groups. Results of the EQ-5D, EQ VAS, and questionnaires regarding subjective symptoms administered at baseline and 2 weeks after each intervention revealed no statistically significant difference in the treatment effects between CDT and SGB. Limitations: Further long-term follow-up studies with a greater number of patients that include analysis according to the severity and duration of symptoms are needed. Conclusions: The results of this study suggest that SGB is an effective treatment for BCRL and may be considered as an alternative to CDT. Key words: Stellate ganglion block, complex decongestive therapy, breast cancer, lymphedema, breast cancer-related lymphedema, quality of life, bioimpedance, secondary lymphedema

scholarly journals Effects of Stellate Ganglion Block on Breast Cancer-Related Lymphedema: Comparison of Various Injectates

2015 ◽  
Vol 18;1 (1;1) ◽  
pp. 93-99
Author(s):  
Jeetinder Kaur Makkar
Keyword(s):  
Breast Cancer ◽  
Stellate Ganglion ◽  
Stellate Ganglion Block ◽  
Ganglion Block ◽  
Upper Arm ◽  
Subjective Data ◽  
Arm Circumference ◽  
Significant Difference ◽  
Group A ◽  
Breast Cancer Related Lymphedema

Background: Stellate ganglion block (SGB) has been reported to be effective in the treatment of breast cancer-related lymphedema (BCRL). Objective: To determine the effects of SGB in BCRL patients and the efficacy of corticosteroids in SGB. Study Design: A double-blinded, randomized, controlled trial. Setting: A single academic hospital, outpatient setting. Methods: In total, 32 patients with BCRL were recruited. Patients were divided randomly into 3 groups (Group A: 0.5% bupivacaine 5 mL, n = 12; Group B: 0.5% bupivacaine 4.5 mL + 20 mg of triamcinolone 0.5 mL, n = 10; and Group C: 0.5% bupivacaine 4 mL + 40 mg of triamcinolone 1 mL, n = 10). All patients received 3 consecutive SGBs, every 2 weeks. The primary outcomes were changes in forearm and upper arm circumference. Circumference was measured at baseline, 2 weeks (before the second injection), 4 weeks (before the third injection), and 8 weeks (one month follow-up after 3 consecutive SGBs). Moreover, subjective data were collected using EORTC C-30 at baseline and 8 weeks. Results: After 3 consecutive SGBs, forearm and upper arm circumferences were decreased significantly from baseline in all groups (P < 0.05/3). The upper arm circumference of group C was reduced significantly more than that of group A (P < 0.05/3). The subjective data by EORTC-C30 at baseline and one month after 3 consecutive SGBs revealed no statistically significant difference. Limitations: Relatively few patients were enrolled. We did not compare SGB with any other BCRL treatment, such as complex decongestive therapy. Conclusions: This study suggests that SGB may be an effective treatment for BCRL. Furthermore, it appears that corticosteroids could have an additive effect in SGB. Key words: Stellate ganglion block, breast cancer, lymphedema:

Sign in / Sign up

Export Citation Format

Share Document